Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer

被引：0

作者：

Takahashi, Toshiaki ^{[1
]}

Yamamoto, Nobuyuki ^{[1
]}

Nukiwa, Toshihiro ^{[2
]}

Mori, Kiyoshi ^{[3
]}

Tsuboi, Masahiro ^{[4
]}

Horai, Takeshi ^{[5
]}

Masuda, Noriyuki ^{[6
]}

Eguchi, Kenji ^{[7
]}

Mitsudomi, Tetsuya ^{[8
]}

Yokota, Soichiro ^{[9
]}

Segawa, Yoshihiko ^{[10
]}

Ichinose, Yukito ^{[11
]}

Fukuoka, Masahiro ^{[12
]}

Saijo, Nagahiro ^{[13
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[2] Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Sendai, Miyagi 980, Japan

[3] Tochigi Canc Ctr, Dept Med Oncol, Div Thorac Oncol, Mibu, Tochigi, Japan

[4] Tokyo Med Univ, Dept Surg, Tokyo, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Thorac Ctr, Tokyo, Japan

[6] Kitasato Univ, Grad Sch Med Sci, Dept Resp Med, Kanagawa, Japan

[7] Tokai Univ, Sch Med, Dept Med Oncol, Kanagawa 2591100, Japan

[8] Aichi Canc Ctr Hosp, Dept Thorac Surg, Aichi, Japan

[9] Toneyama Natl Hosp, Natl Hosp Org, Dept Resp Med, Osaka, Japan

[10] Shikoku Canc Ctr, Natl Hosp Org, Dept Med & Thorac Oncol, Shikoku, Ehime, Japan

[11] Kyushu Natl Canc Ctr, Natl Hosp Org, Dept Thorac Oncol, Fukuoka, Japan

[12] Kinki Univ, Sch Med, Dept Med Oncol, Osaka 589, Japan

[13] Natl Canc Ctr Hosp E, Chiba, Japan

来源：

ANTICANCER RESEARCH | 2010年 / 30卷 / 02期

关键词：

Non-small cell lung cancer; erlotinib; Tarceva; EGFR-TKIs; EGFR mutation; phase II; TYROSINE-KINASE INHIBITOR; SOLID TUMORS; PHARMACOKINETICS; EFFICACY; BENEFIT; GEFITINIB; SURVIVAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC). Patients and Methods: This was a multicentre, open-label phase 11 study of erlotinib (150 mg/day) in patients with stage IIIB or IV NSCLC. The primary endpoint was the objective tumour response rate. Results: Of the 46 patients, 13 were assessed to have a partial response and 9 had stable disease. The median duration of response was 449 days and time to progression vas 75 days. Median overall survival (OS) was 13.5 months and the 1-year survival rate was 56.5%. The most common adverse events were dermal or gastrointestinal, and were mainly grade 2 or less. An exploratory analysis suggested a link between rash severity and OS. Conclusion: Erlotinib has promising antitumour activity and is generally well tolerated in Japanese patients with previously treated NSCLC.

引用

页码：557 / 563

页数：7

共 50 条

[1] Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer
Horiike, Atsushi
Yamamoto, Nobuyuki
Tanaka, Hisashi
Yanagitani, Noriko
Kudo, Keita
Ohyanagi, Fumiyoshi
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Horai, Takeshi
Nishio, Makoto
ANTICANCER RESEARCH, 2014, 34 (04) : 1975 - 1981
[2] Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer A Phase II Study
Kubota, Kaoru
Nishiwaki, Yutaka
Tamura, Tomohide
Nakagawa, Kazuhiko
Matsui, Kaoru
Watanabe, Koshiro
Hida, Toyoaki
Kawahara, Masaaki
Katakami, Nobuyuki
Takeda, Kohi
Yokoyama, Akira
Noda, Kazumasa
Fukuoka, Masahiro
Saijo, Nagahiro
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (12) : 1439 - 1445
[3] Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
Halmos, Balazs
Pennell, Nathan A.
Fu, Pingfu
Saad, Shumaila
Gadgeel, Shirish
Otterson, Gregory A.
Mekhail, Tarek
Snell, Michael
Kuebler, Philip
Sharma, Neelesh
Dowlati, Afshin
ONCOLOGIST, 2015, 20 (11) : 1298 - 1303
[4] Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer
Emoto-Yamamoto, Y.
Iida, S.
Kawanishi, T.
Fukuoka, M.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (02) : 232 - 239
[5] Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer
Garon, Edward B.
Siegfried, Jill M.
Stabile, Laura P.
Young, Patricia A.
Marquez-Garban, Diana C.
Park, David J.
Patel, Ravi
Hu, Eddie H.
Sadeghi, Saeed
Parikh, Rupesh J.
Reckamp, Karen L.
Adams, Brad
Elashoff, Robert M.
Elashoff, David
Grogan, Tristan
Wang, He-Jing
Dacic, Sanja
Brennan, Meghan
Valdes, Yacgley
Davenport, Simon
Dubinett, Steven M.
Press, Michael F.
Slamon, Dennis J.
Pietras, Richard J.
LUNG CANCER, 2018, 123 : 91 - 98
[6] Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
Gerber, David E.
Boothman, David A.
Fattah, Farjana J.
Dong, Ying
Zhu, Hong
Skelton, Rachel A.
Priddy, Laurin L.
Vo, Peggy
Dowell, Jonathan E.
Sarode, Venetia
Leff, Richard
Meek, Claudia
Xie, Yang
Schiller, Joan H.
LUNG CANCER, 2015, 90 (03) : 534 - 541
[7] Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study
Stathopoulos, G. P.
Trafalis, D.
Dimitroulis, J.
Athanasiou, A.
Koutantos, J.
Anagnostopoulos, A.
ONCOLOGY LETTERS, 2010, 1 (02) : 335 - 338
[8] A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
Clement-Duchene, Christelle
Natale, Ronald B.
Jahan, Thierry
Krupitskaya, Yelena
Osarogiagbon, Raymond
Sanborn, Rachel E.
Bernstein, Eric D.
Dudek, Arkadiusz Z.
Latz, Jane E.
Shi, Peipei
Wakelee, Heather A.
LUNG CANCER, 2012, 78 (01) : 57 - 62
[9] Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer
Platania, Marco
Agustoni, Francesco
Formisano, Barbara
Vitali, Milena
Ducceschi, Monika
Pietrantonio, Filippo
Zilembo, Nicoletta
Gelsomino, Francesco
Pusceddu, Sara
Buzzoni, Roberto
TARGETED ONCOLOGY, 2011, 6 (03) : 181 - 186
[10] Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets
Lee, Dae Ho
Kim, Sang-We
Suh, Cheolwon
Han, Yun Hee
Lee, Jung-Shin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 35 - 39

← 1 2 3 4 5 →